Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC


Professor of Medicine
Hofstra Northwell School of Medicine

Feinstein Investigator – Center for Heart and Lung Research
The Feinstein Institute for Medical Research

System Director – Anticoagulation and Clinical Thrombosis Services
Northwell Health System

Alex C. Spyropoulos, MD received his medical degree from the University of Pennsylvania School of Medicine in Philadelphia. He completed his internship and residency in internal medicine at the University of New Mexico Health Sciences Center in Albuquerque, NM. He is board certified in Internal Medicine.

Dr. Spyropoulos was Founder and former Medical Director of the Clinical Thrombosis Center in Albuquerque, New Mexico. He is currently a Professor of Medicine at Hofstra, Northwell School of Medicine and System Director of Anticoagulation and Clinical Thrombosis Services for the multi hospital Northwell Health System in NY. He is co-chair of the Council on Leadership of Thrombosis at Northwell Health System. He is also a Feinstein Investigator for the Center for Heart and Lung Research as part of the Feinstein Institute of Medical Research. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and the Royal College of Physicians, Canada.

Dr. Spyropoulos has helped to develop protocols using LMWH in outpatient-based treatment of venous thromboembolic disease, patient self-testing of warfarin, perioperative “bridging” for patients on chronic anticoagulation, medical inpatient thromboprophylaxis, protocols with regards to the use of anticoagulants for HIT, and clinical use of the novel oral anticoagulants, including their use in special patient populations. Dr. Spyropoulos is active in assessing outcome and pharmacoeconomic analyses of these protocols and has lectured extensively both nationally and internationally on these issues.

He has been involved as Principal Investigator, Scientific Committee member, Steering Committee member, or member of Data Safety Monitoring Board in multiple international, multicenter randomized trials in thrombosis. He is a Steering Committee member of the NHLBI BRIDGE and Kids DOTT studies and the CIHR PAUSE trial. He is the co-Chair of the Executive Committee for MARINER, a global Phase 3 multicenter study of thromboprophylaxis in medical patients with rivaroxaban, He is a founding member of ATLAS, a US-based ARO-CRO in thrombosis-related research. He is a panel member of a US national experts consensus group for clinical excellence in thrombosis management, a member of the Anticoagulation Forum and the Thrombosis/Haemostasis Society of North America, co-Chair of the Scientific Standardization Committees of Predictive Variables and Perioperative Thrombosis and Haemostasis as part of ISTH, and co-author for the 8th, 9th and currently 10th ACCP Antithrombotic Guidelines in Perioperative Anticoagulants, the 2008 International Consensus Statement Guidelines in Venous Thromboembolism, and senior author for the 2013 International Consensus Statement on venous thromboembolic disease. He is also reviewer for the 2014 ESC Guidelines on Pulmonary Embolism. He is Section Editor for Thrombosis and Haemostasis, and is on the editorial staff for Thrombosis Research and Hospital Medicine. He is a reviewer for many journals.

Dr. Spyropoulos’ articles, letters, and editorials have been published in over 160 peer-reviewed journals including The New England Journal of Medicine, Blood, Circulation, American Journal of Hematology, American Journal of Medicine, Chest, Thrombosis Haemostasis, American Journal of Cardiology, Journal of Thrombosis and Haemostasis , Journal of the American College of Cardiology, Clinical Applied Thrombosis Haemostasis, and Thrombosis Research,.


Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.

Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering (ATLAS) Group.

Cost-of-illness model for venous thromboembolism.

Mahan CE, Barco S, Spyropoulos AC.

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.

Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman MV, Jamieson DG, Levy JH, Pollack CV Jr, Spyropoulos AC, Steiner T, Del Zoppo GJ, Eikelboom J.

Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients.

Greene MT, Spyropoulos AC, Chopra V, Grant PJ, Kaatz S, Bernstein SJ, Flanders SA.

Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis.

Zahid MF, Murad MH, Litzow MR, Hogan WJ, Patnaik MS, Khorana A, Spyropoulos AC, Hashmi SK.

European Union-28: An annualised cost-of-illness model for venous thromboembolism.

Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE.

For additional research publications please visit: https://www.researchgate.net/profile/Alex_Spyropoulos